AR072798A1 - Derivados de pirido-piridinonas, su preparacion, composicion farmaceutica y su uso en el tratamiento de las enfermedades ligadas a la actividad de la proteina quinasa - Google Patents
Derivados de pirido-piridinonas, su preparacion, composicion farmaceutica y su uso en el tratamiento de las enfermedades ligadas a la actividad de la proteina quinasaInfo
- Publication number
- AR072798A1 AR072798A1 ARP090102532A ARP090102532A AR072798A1 AR 072798 A1 AR072798 A1 AR 072798A1 AR P090102532 A ARP090102532 A AR P090102532A AR P090102532 A ARP090102532 A AR P090102532A AR 072798 A1 AR072798 A1 AR 072798A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- atom
- alkyl group
- optionally substituted
- carbon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Reivindicacion 1: Compuesto que responde a la formula (1), R1 representa un grupo alquilo C1-4; R2 representa -(CH)n'-B en el que n' = 0, 1, 2, 3, 4 y B es un grupo cicloalquilo C3-5 o un grupo alquilo C1-4 sustituido opcionalmente con uno o varios átomos de fluor, un grupo alcoxi C1-4; U representa un grupo carbonilo o un grupo -CH2-; Y, Z, V y W representan, independientemente los unos de los otros un grupo -CH- o un átomo de carbono sustituido opcionalmente con un grupo R7 o un heteroátomo tal como un átomo de nitrogeno o un átomo de azufre o un oxigeno, o sin átomo, entendiéndose que el ciclo debe ser aromático y comprender entre 5 y 6 eslabones; R3, R4 representan independientemente el uno del otro un átomo de hidrogeno o un grupo alquilo C1-4 lineal, o R3 y R4 forman junto con el carbono al que están unidos un grupo cicloalquilo C3-5; m es un numero entero igual a 1, 2, 3, 4; R5 representa un átomo de hidrogeno o un grupo alquilo C1-4; R6 representa -(CH2)n-L en el que n = 0, 1, 2, 3 y L es un grupo seleccionado independientemente entre los grupos siguientes: un grupo alquilo C1-5 sustituido opcionalmente con un grupo alcoxi C1-4; un grupo cicloalquilo C3-5; un arilo que comprende 6 átomos de carbono y sustituido opcionalmente con uno o varios átomos de halogenos; un heteroarilo que comprende entre 5 y 6 eslabones con al menos un heteroátomo elegido entre un átomo de nitrogeno o de azufre, sustituido opcionalmente con un grupo alquilo C1-4; un heterociclo saturado en el que dicho heterociclo comprende entre 4 y 7 eslabones con al menos un heteroátomo elegido entre un átomo de nitrogeno, un átomo de oxígeno y está sustituido opcionalmente en cualquier posicion, incluido sobre el átomo de nitrogeno con uno o varios sustituyentes elegidos entre un átomo de fluor, un grupo fluoroalquilo C1-4, un grupo alquilo C1-4 lineal o ramificado, un grupo cicloalquilo C3-5 o un grupo alquil C1-4 sulfonamida, pudiendo ser la configuracion absoluta de un carbono sustituido sobre dicho heterociclo R o S, o racémica; R7 representa un átomo de hidrogeno o un grupo alquilo C1-4 o un átomo de halogeno; en el estado de base o de sal de adicion a un ácido, en el estado de solvato, así como sus enantiomeros y diastereoisomeros, incluidas sus mezclas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0803862A FR2933700B1 (fr) | 2008-07-08 | 2008-07-08 | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072798A1 true AR072798A1 (es) | 2010-09-22 |
Family
ID=40219672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102532A AR072798A1 (es) | 2008-07-08 | 2009-07-07 | Derivados de pirido-piridinonas, su preparacion, composicion farmaceutica y su uso en el tratamiento de las enfermedades ligadas a la actividad de la proteina quinasa |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8436011B2 (es) |
| EP (1) | EP2315767B1 (es) |
| JP (1) | JP5606434B2 (es) |
| KR (1) | KR20110031372A (es) |
| CN (1) | CN102149713B (es) |
| AR (1) | AR072798A1 (es) |
| AU (1) | AU2009267827B2 (es) |
| BR (1) | BRPI0915438A2 (es) |
| CA (1) | CA2729833A1 (es) |
| CL (1) | CL2011000048A1 (es) |
| CO (1) | CO6341476A2 (es) |
| CR (1) | CR11866A (es) |
| DO (1) | DOP2011000008A (es) |
| EA (1) | EA019362B1 (es) |
| EC (1) | ECSP11010742A (es) |
| ES (1) | ES2438540T3 (es) |
| FR (1) | FR2933700B1 (es) |
| HK (1) | HK1159108A1 (es) |
| HN (1) | HN2011000076A (es) |
| IL (1) | IL210514A (es) |
| MA (1) | MA32544B1 (es) |
| MX (1) | MX2011000330A (es) |
| MY (1) | MY149705A (es) |
| NI (1) | NI201100011A (es) |
| NZ (1) | NZ590862A (es) |
| PE (1) | PE20110405A1 (es) |
| SV (1) | SV2011003800A (es) |
| TW (1) | TW201004955A (es) |
| UA (1) | UA102858C2 (es) |
| UY (1) | UY31971A (es) |
| WO (1) | WO2010004197A2 (es) |
| ZA (1) | ZA201100210B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205455D0 (en) | 2002-03-07 | 2002-04-24 | Molecular Sensing Plc | Nucleic acid probes, their synthesis and use |
| FR2933700B1 (fr) | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| FR2952934B1 (fr) * | 2009-11-23 | 2012-06-22 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| FR2954943B1 (fr) * | 2010-01-07 | 2013-03-01 | Sanofi Aventis | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique |
| FR2955109B1 (fr) * | 2010-01-08 | 2012-09-07 | Sanofi Aventis | Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| EP2524915A1 (en) | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| WO2014012942A1 (en) * | 2012-07-17 | 2014-01-23 | Sanofi | Use of vegfr-3 inhibitors for treating hepatocellular carcinoma |
| UA110688C2 (uk) * | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| CN111344287B (zh) | 2017-11-14 | 2023-12-19 | 默沙东有限责任公司 | 作为吲哚胺2，3-双加氧酶(ido)抑制剂的新型取代的联芳基化合物 |
| US11498904B2 (en) | 2017-11-14 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| KR20200104873A (ko) * | 2017-12-06 | 2020-09-04 | 린 바이오사이언스, 피티와이 엘티디. | 튜불린 억제제 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845008A (en) * | 1973-03-02 | 1974-10-29 | Du Pont | Brake lining composition comprising particulate tar residue |
| US4959363A (en) * | 1989-06-23 | 1990-09-25 | Sterling Drug Inc. | Quinolonecarboxamide compounds, their preparation and use as antivirals. |
| EP0610231A1 (en) * | 1992-09-09 | 1994-08-17 | STACKPOLE Limited | Powder metal alloy process |
| US5332422A (en) * | 1993-07-06 | 1994-07-26 | Ford Motor Company | Solid lubricant and hardenable steel coating system |
| AU7811194A (en) * | 1993-10-02 | 1995-05-01 | Cerasiv Gmbh | Molded article |
| US5518639A (en) * | 1994-08-12 | 1996-05-21 | Hoeganaes Corp. | Powder metallurgy lubricant composition and methods for using same |
| US5641580A (en) * | 1995-10-03 | 1997-06-24 | Osram Sylvania Inc. | Advanced Mo-based composite powders for thermal spray applications |
| JP3537286B2 (ja) * | 1997-03-13 | 2004-06-14 | 株式会社三協精機製作所 | 焼結含油軸受およびそれを用いたモータ |
| CA2207579A1 (fr) * | 1997-05-28 | 1998-11-28 | Paul Caron | Piece frittee a surface anti-abrasive et procede pour sa realisation |
| US6689424B1 (en) * | 1999-05-28 | 2004-02-10 | Inframat Corporation | Solid lubricant coatings produced by thermal spray methods |
| EP1338679B1 (en) * | 2000-11-16 | 2010-09-22 | Honda Giken Kogyo Kabushiki Kaisha | Metallic sliding member and method of surface-treating thereof |
| JP2004124130A (ja) * | 2002-09-30 | 2004-04-22 | Fujimi Inc | 溶射用粉末及びその製造方法並びに該溶射用粉末を用いた溶射方法 |
| US7300488B2 (en) * | 2003-03-27 | 2007-11-27 | Höganäs Ab | Powder metal composition and method for producing components thereof |
| TW200502236A (en) * | 2003-03-28 | 2005-01-16 | Hoffmann La Roche | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| DE10326769B3 (de) * | 2003-06-13 | 2004-11-11 | Esk Ceramics Gmbh & Co. Kg | Dauerhafte BN-Formtrennschichten für das Druckgießen von Nichteisenmetallen |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| EP1664030A1 (en) * | 2003-09-16 | 2006-06-07 | AstraZeneca AB | Quinazoline derivatives |
| US7553564B2 (en) * | 2004-05-26 | 2009-06-30 | Honeywell International Inc. | Ternary carbide and nitride materials having tribological applications and methods of making same |
| US7968503B2 (en) * | 2004-06-07 | 2011-06-28 | Ppg Industries Ohio, Inc. | Molybdenum comprising nanomaterials and related nanotechnology |
| US7687112B2 (en) * | 2004-07-14 | 2010-03-30 | Kinetitec Corporation | Surface for reduced friction and wear and method of making the same |
| GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| DE102005001198A1 (de) * | 2005-01-10 | 2006-07-20 | H.C. Starck Gmbh | Metallische Pulvermischungen |
| US7470307B2 (en) * | 2005-03-29 | 2008-12-30 | Climax Engineered Materials, Llc | Metal powders and methods for producing the same |
| US7575619B2 (en) * | 2005-03-29 | 2009-08-18 | Hitachi Powdered Metals Co., Ltd. | Wear resistant sintered member |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| EP2097416B1 (en) * | 2006-12-18 | 2012-09-12 | Amgen, Inc | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| FR2917413B1 (fr) * | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique |
| FR2917412B1 (fr) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique |
| WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
| FR2933700B1 (fr) | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| FR2933701A1 (fr) * | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| US8038760B1 (en) * | 2010-07-09 | 2011-10-18 | Climax Engineered Materials, Llc | Molybdenum/molybdenum disulfide metal articles and methods for producing same |
-
2008
- 2008-07-08 FR FR0803862A patent/FR2933700B1/fr not_active Expired - Fee Related
-
2009
- 2009-07-03 TW TW098122666A patent/TW201004955A/zh unknown
- 2009-07-06 PE PE2011000014A patent/PE20110405A1/es not_active Application Discontinuation
- 2009-07-06 CA CA2729833A patent/CA2729833A1/fr not_active Abandoned
- 2009-07-06 CN CN2009801348457A patent/CN102149713B/zh not_active Expired - Fee Related
- 2009-07-06 WO PCT/FR2009/051321 patent/WO2010004197A2/fr active Application Filing
- 2009-07-06 UA UAA201101399A patent/UA102858C2/ru unknown
- 2009-07-06 JP JP2011517200A patent/JP5606434B2/ja not_active Expired - Fee Related
- 2009-07-06 EA EA201170154A patent/EA019362B1/ru not_active IP Right Cessation
- 2009-07-06 MX MX2011000330A patent/MX2011000330A/es active IP Right Grant
- 2009-07-06 BR BRPI0915438A patent/BRPI0915438A2/pt not_active IP Right Cessation
- 2009-07-06 AU AU2009267827A patent/AU2009267827B2/en not_active Ceased
- 2009-07-06 ES ES09784467.4T patent/ES2438540T3/es active Active
- 2009-07-06 KR KR1020117002883A patent/KR20110031372A/ko not_active Application Discontinuation
- 2009-07-06 MY MYPI2011000087A patent/MY149705A/en unknown
- 2009-07-06 EP EP09784467.4A patent/EP2315767B1/fr not_active Not-in-force
- 2009-07-06 NZ NZ590862A patent/NZ590862A/en not_active IP Right Cessation
- 2009-07-07 AR ARP090102532A patent/AR072798A1/es unknown
- 2009-07-08 UY UY0001031971A patent/UY31971A/es not_active Application Discontinuation
-
2010
- 2010-12-22 CR CR11866A patent/CR11866A/es not_active Application Discontinuation
-
2011
- 2011-01-05 EC EC2011010742A patent/ECSP11010742A/es unknown
- 2011-01-06 US US12/985,749 patent/US8436011B2/en not_active Expired - Fee Related
- 2011-01-06 IL IL210514A patent/IL210514A/en not_active IP Right Cessation
- 2011-01-07 ZA ZA2011/00210A patent/ZA201100210B/en unknown
- 2011-01-07 SV SV2011003800A patent/SV2011003800A/es unknown
- 2011-01-07 CO CO11001537A patent/CO6341476A2/es active IP Right Grant
- 2011-01-07 CL CL2011000048A patent/CL2011000048A1/es unknown
- 2011-01-07 HN HN2011000076A patent/HN2011000076A/es unknown
- 2011-01-07 DO DO2011000008A patent/DOP2011000008A/es unknown
- 2011-01-07 NI NI201100011A patent/NI201100011A/es unknown
- 2011-02-08 MA MA33590A patent/MA32544B1/fr unknown
- 2011-12-21 HK HK11113761.7A patent/HK1159108A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072798A1 (es) | Derivados de pirido-piridinonas, su preparacion, composicion farmaceutica y su uso en el tratamiento de las enfermedades ligadas a la actividad de la proteina quinasa | |
| DOP2019000083A (es) | COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR079077A1 (es) | Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica de enfermedades mediadas por la tirosina quinasa | |
| ES2624795T3 (es) | Derivados de N-(heteroaril)-1-heteroaril-1H-indol-2-carboxamidas, su preparación y su aplicación en terapéutica | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR061642A1 (es) | Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas | |
| AR072488A1 (es) | Derivados heterociclicos de 1,2,4-triazol, agonistas de receptores beta 2 adrenergicos y antagonistas muscarinicos colinergicos, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de afecciones respiratorias, inflamatorias y alergicas. | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| AR098432A1 (es) | Compuestos heterocíclicos | |
| CO6331462A2 (es) | Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa | |
| AR093503A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
| UY32801A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR073565A1 (es) | Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
| CR9499A (es) | Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR051612A1 (es) | Quinolinas como intensificadores alostericos de receptores gaba-b | |
| AR063328A1 (es) | Derivados indolicos su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| DOP2006000254A (es) | Nuevos derivados de indolizina, su proceso de preparación y las composiciones terapéuticas que los comprenden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |